WASHINGTON, LONDON and HONG KONG, March 28, 2012 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, announced that Neil J. Campbell, President and CEO, will be presenting at the 11th Annual Needham Healthcare Conference on April 4, 2012 at 2:20 p.m. ET at the New York Palace 455 Madison Avenue, New Yorkin the Chairman's Conference Room.
The presentation will include an overview of SuperNova's proprietary point-of-care (POC) and point-of-use (POU) diagnostic technology and an update on the company's commercial partnership with Concile, GmbH. A live webcast and 90 day archive of the presentation will be available at http://wsw.com/webcast/needham51/snva/.
Mr. Campbell stated, "The Annual Needham Healthcare Conference provides an ideal forum for investors to gain a fuller understanding of Supernova's AmpCrystal® platform and the revenue potential for this highly differentiated POC/POU technology. In particular, I look forward to highlighting the array of diagnostic capabilities that AmpCrystal provides for point of interest settings in human and non-human applications as well as improving central laboratory assays."
About SuperNova Diagnostics®, Inc.
SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. A powerful proprietary nanochemistry, AmpCrystal®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNova® Putting the Laboratory in the Palm of Your Hand®. For additional information, please visit www.supernovadiagnostics.com.
Tiberend Strategic Advisors, Inc.
SOURCE SuperNova Diagnostics, Inc.